Its important to get this info as soon as possible as many of these Kaiser patients in this trial profile know the efficacy of their 3rd Covid shot ( the booster ) and the original shots .....has probably worn off.
So come April we know our Covid shots have lost most of their protection . Whats next before the next variant or the expected winter re emergence ?
IF Vascepa reduces hospitalization , need for urgent care etc by at least 15% with a stat significance P value of .01 or better ....I expect Kaiser to prescribe / offer Vascepa to all their patients that meet the MITIGATE profile